1-8 of 8
Fredrik Borgsten
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Paula Rodriguez Otero, Meletios A. Dimopoulos, Tomoaki Fujisaki, Jae Hoon Lee, Susan Wroblewski, Fredrik Borgsten, Robin Carson, Rui Liu, Man Zhao, Tingting Wu, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2006.
https://doi.org/10.1182/blood-2023-180809
Published: 2023
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Thierry Facon, Shaji K Kumar, Katja Weisel, Saad Usmani, Philippe Moreau, Torben Plesner, Robert Z. Orlowski, Nizar Jacques Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Robin Carson, Fredrik Borgsten, Hartmut Goldschmidt
Journal: Blood
Blood (2022) 140 (Supplement 1): 10133–10136.
https://doi.org/10.1182/blood-2022-163555
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Shaji K Kumar, Philippe Moreau, Nizar Jacques Bahlis, Thierry Facon, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 10150–10153.
https://doi.org/10.1182/blood-2022-163335
Published: 2022
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Maria-Victoria Mateos, Jesús San-Miguel, Michele Cavo, Joan Bladé Creixenti, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Meletios A. Dimopoulos
Journal: Blood
Blood (2022) 140 (Supplement 1): 10157–10159.
https://doi.org/10.1182/blood-2022-163347
Published: 2022
Journal Articles

Healthcare Resource Utilization and Sickness Absence in Newly Diagnosed Multiple Myeloma Patients in Sweden: Trends in a Changing Treatment Landscape

Fredrik Borgsten, MD, Xenia Gatopoulou, MBA, Marta Pisini, MBA, Magnus Tambour, PhD, Frida Schain, PhD, Christina V Jones, PhD, Kelvin Ho Man Kwok, PhD, Catharina Hjortsberg, PhD, Magnus Björkholm, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137498
Published: 2020
Journal Articles

Predictors of Overall Survival for Multiple Myeloma Patients Depending on Transplant Status According to a Retrospective, Non-Interventional Study in Norway

Fredrik H. Schjesvold, MD PhD, Anderson Jenna, Jaak Sõnajalg, Amy Leval, PhD, Anna Lysén, MSc, Saeeda Rana, Päivi Castren-Kortekangas, Fredrik Borgsten
Journal: Blood
Blood (2018) 132 (Supplement 1): 5759.
https://doi.org/10.1182/blood-2018-99-114474
Published: 2018